Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28432280 | 1.00 | SLC9A1 (0.45) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL29352246 | 1.00 | SLC9A1 (0.45) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL29399678 | 0.94 | SLC9A1 (0.50) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| Fluoride Ion SCHEMBL6345 | 0.92 | SLC9A1 (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| Phosphine SCHEMBL30298295 | 0.92 | SLC9A1 (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| Bromide SCHEMBL30556235 | 0.92 | SLC9A1 (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| Hydrochloric Acid SCHEMBL30591144 | 0.92 | SLC9A1 (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| Hydrochloric Acid SCHEMBL3737085 | 0.92 | SLC9A1 (0.49) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| Phosphoric Acid SCHEMBL29515149 | 0.92 | NPSR1 (0.39) | SLC9A1KEAP1TSHRNPSR1RXFP1 | |
| SCHEMBL26920850 | 0.92 | NPSR1 (0.39) | SLC9A1KEAP1TSHRNPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340518-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | GLENMARK LIFE SCIENCES LTD (IN) | 2025-11-06 | — | — | US | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| CN-119874685-A | Shearing inhibitor for pre-miR-21 post-transcriptional processing and preparation method and application thereof | 广东工业大学 | 2025-04-25 | — | — | CN | claimed |
| EP-4536226-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | Alivus Life Sciences Limited (IN) | 2025-04-16 | — | — | EP | claimed |
| US-20250074918-A1 | THIOPHENE DERIVATIVES PREPARING | GANZHOU HEMAY PHARMACEUTICAL, CO., LTD (CN) | 2025-03-06 | — | — | US | claimed |
| CN-119241449-A | Piperazine derivative and preparation method and application thereof | 重庆市畜牧科学院 | 2025-01-03 | — | — | CN | claimed |
| US-12163009-B2 | Reinforced biodegradable polymer nanocomposite and method of manufacture thereof | TORAPHENE LTD (GB) | 2024-12-10 | — | — | US | claimed |
| US-20240351989-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | ALIVUS LIFE SCIENCES LIMITED (IN) | 2024-10-24 | — | — | US | claimed |
| CN-118416285-A | Preparation method and application of drug-loaded oil for interventional operation | 太阳雨林（厦门）生物医药有限公司 | 2024-08-02 | — | — | CN | claimed |
| EP-4384501-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | Glenmark Life Sciences Limited (IN) | 2024-06-19 | — | — | EP | claimed |
| WO-2020225831-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)PYRROLIDIN-2-YL] IMIDAZO[1,5-A]PYRAZIN-1-YL)}-N-(PYRIDINE-2-YL)BENZAMIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2020-11-12 | — | — | WO | claimed |
| EP-3676265-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | Bayer Animal Health GmbH (DE) | 2020-07-08 | — | — | EP | claimed |
| CN-111094281-A | Chemical process for the preparation of monobactam antibiotics and intermediates thereof | 诺华股份有限公司 | 2020-05-01 | — | — | CN | claimed |
| EP-3500646-A1 | CHEMISTRY FOR FINES FIXING AND WATER CONTROL | Commonwealth Scientific and Industrial Research Organisation (AU) | 2019-06-26 | — | — | EP | claimed |
| US-10293055-B2 | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2019-05-21 | — | — | US | claimed |
| US-20190055433-A1 | UV-CROSSLINKED HOT-MELT PRESSURE-SENSITIVE ADHESIVE USED FOR POLYVINYL-CHLORIDE INSULATED ADHESIVE TAPE | HEBEI YONGLE TAPE CO LTD | 2019-02-21 | — | — | US | claimed |
| WO-2018185715-A1 | IMPROVED PROCESS FOR THE PREPARATION OF N6-[2-(METHYLTHIO)ETHYL]-2-[(3,3,3-TRIFLUOROPROPYL)THIO]-5'-ADENYLIC ACID, MONOANHYDRIDE WITH (DICHLOROMETHYLENE) BISPHOSPHONIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-10-11 | — | — | WO | claimed |
| WO-2018032051-A1 | CHEMISTRY FOR FINES FIXING AND WATER CONTROL | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2018-02-22 | — | — | WO | claimed |
| US-9839687-B2 | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2017-12-12 | — | — | US | claimed |
| EP-1981846-B1 | MARKERS, METHOD FOR MANUFACTURING THEM AND THEIR APPLICATIONS | LABORATOIRES SYNTH-INNOVE (FR) | 2017-11-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340518-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | BRAF, KRAS, JAK2 | SLC9A1 678/4885KEAP1 232/4885TSHR 3436/4885 |
| US-20240351989-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | PARP1, PARP2, PARP4 | SLC9A1 2145/4885KEAP1 1993/4885TSHR 3665/4885 |
| US-10293055-B2 | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule | AADAC, EPCAM, DCLRE1A | SLC9A1 4532/4885KEAP1 2918/4885TSHR 2628/4885 |
| US-20250074918-A1 | THIOPHENE DERIVATIVES PREPARING | TYMP, CYP3A4, CYP4F2 | SLC9A1 4644/4885KEAP1 417/4885TSHR 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.